This Schedule 14D-9C consists of a transcript of the presentation by
certain members of management of each of Wright Medical Group N.V. (“Wright”) and Stryker Corporation to Wright employees that occurred on November 6, 2019 and relates to the proposed acquisition of Wright pursuant to the terms of a
Purchase Agreement, dated as of November 4, 2019, by and among Wright, Stryker Corporation and Stryker B.V. A copy of the transcript, which was first used or made available on November 18, 2019, is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This communication includes forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual
results to differ materially from those implied by the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent,
belief or current expectation of Wright and members of its senior management team and can typically be identified by words such as “believe,” “expect,” “estimate,” “predict,” “target,”
“potential,” “likely,” “continue,” “ongoing,” “could,” “should,” “intend,” “may,” “might,” “plan,” “seek,” “anticipate,”
“project” and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the proposed transaction, prospective performance, future plans, events,
expectations, performance, objectives and opportunities and the outlook for Wright’s business; the commercial success of Wright’s products, including the ability to achieve wide market acceptance of Wright’s products due to clinical,
regulatory, cost reimbursement and other issues; filings and approvals relating to the proposed transaction; the expected timing of the completion of the proposed transaction; the ability to complete the proposed transaction considering the various
closing conditions; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned
not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ
from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and other proposed transactions; uncertainties as to how many of Wright’s shareholders will tender their shares in the
offer or approve the resolutions to be solicited at the extraordinary general meeting of Wright’s shareholders (the “EGM”); the possibility that various closing conditions for the proposed transaction may not be satisfied or waived,
including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the purchase
agreement; the effects of the proposed transaction (or the announcement thereof) on relationships with associates, customers, other business partners or governmental entities; transaction costs; the risk that the proposed transaction will divert
management’s attention from Wright’s ongoing business operations; changes in Wright’s businesses during the period between now and the closing; risks associated with litigation; and other risks and uncertainties detailed from time to
time in documents filed with the Securities and Exchange Commission (the “SEC”) by Wright, including current reports on Form 8-K, quarterly reports on Form
10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9, proxy statement and other documents to be filed by Wright.
All forward-looking statements are based on information currently available to Wright, and Wright assumes no obligation to update any forward-looking statements.
IMPORTANT INFORMATION FOR INVESTORS AND SECURITY HOLDERS
The tender offer for Wright’s outstanding ordinary shares referenced herein has not yet commenced. This communication is not a
recommendation, an offer to purchase or a solicitation of an offer to sell ordinary shares of Wright or any other securities. This communication may be deemed to be solicitation material in respect of the EGM Proposals (defined below). At the time
the tender offer is commenced, Stryker will file with the SEC a Tender Offer Statement on Schedule TO, and Wright will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9. Wright also
intends to file with the SEC a proxy statement in connection with the EGM, at which Wright’s shareholders will vote on certain proposed resolutions (the “EGM Proposals”) in connection with the transactions referenced herein, and will
mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the EGM. SHAREHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT (INCLUDING THE OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER
DOCUMENTS), THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 AND THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO ANY OF THE